secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEUROCRINE BIOSCIENCES INC (NBIX)
CIK:        0000914475
Form:       8-K
Filed at:   2023-05-19T23:59:59+00:00
Accession:  0001193125-23-149520
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Neurocrine shareholders approve amended 2020 equity plan and elect directors at 2023 annual meeting
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2020 Equity Incentive Plan with 84.95% of votes cast in favor.
- Three Class III directors elected: Kevin Gorman, Gary Lyons, Johanna Mercier.
- Advisory say-on-pay approved with 93.11% support; future say-on-pay votes to be held annually.
- Ernst & Young ratified as independent auditor for FY2023 with 92.82% support.
- No financial guidance or earnings reported; meeting focused on governance matters.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/914475/000119312523149520/0001193125-23-149520-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/914475/000119312523149520/d494976d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-149520

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer